1. The influence of circulating 5-hydroxytryptamine (serotonin) on small intestinal motility was investigated in healthy volunteers. 2. Small intestinal motility was studied by means of a constantly perfused multi-channel manometry tube, connected to a computer system. 3. Intravenous infusions of either 5-hydroxytryptamine at increasing doses or saline were given over a period of 4 h. 4. 5-Hydroxytryptamine infusion dodependently increased plasma 5-hydroxytryptamine from approximately 2 to 10 and 25 nmol/l respectively, as well as urinary excretions of 5-hydroxytryptamine and 5-hydroxyindole acetic acid, a major 5-hydroxytryptamine metabolite. 5. The number of phase 111 of the migrating motor complex originating in the small intestine was dosedependently increased by 5-hydroxytryptamine, and found to correlate to the plasma concentration of 5-hydroxytryptamine. The fraction of phase III also increased at the expense of phase 11 activity. In addition, 5-hydroxytryptamine increased the motility index, propagation velocity of phase III activity and the amplitude of contractions during phase III.
INTRODUCTION
The biogenic amine 5-hydroxytryptamine serotonin) is present in the enterochromaffin cells of the mucosa [l] and in nerve cells of the myenteric plexus [2, 3] in the gastrointestinal tract. Occasionally, 5-HT can also be found together with various neuropeptides such as somatostatin, substance P and vasoactive intestinal peptide in gut neurons [4] . In blood, 5-HT is predominantly stored in platelets, and may be released by activation of these cells. The fate of intravenously infused 5-HT has not been studied in humans, but animal experiments have shown that 5-HT is rapidly removed from the circulation [5, 6] , presumably due to uptake by platelets and endothelial cells, as well as by metabolism.
5-HT has been shown to stimulate gastrointestinal motility in man, both in vitro and in vivo [7, 8] . However, these studies were carried out before the recognition of the migrating motor complex (MMC) in man [9] . Insights into the control of gastrointestinal motility may be studied through analysis of the MMC, since this is the only motor pattern that can be predicted to recur within a certain, though variable, time interval. The effects of 5-HT on MMC have been most extensively studied in animals [ 10-121, while human studies are few. Serotoninergic mechanisms may be involved in the regulation of MMC in man, as suggested by the finding that treatment with a selective 5-HT reuptake inhibitor, paroxetine, shortens the MMC interval and increases the propagation velocity of phase I11 of MMC in the proximal jejunum [13] . Furthermore, we have previously found that bolus injections of 5-HT given intravenously induce phase 111-like activity in the small intestine of healthy volunteers [14] .
5-HT exerts its effects through interactions with different receptor subtypes on nerves and muscle cells in the small intestine. A number of 5-HT receptor subtypes exist. Seven main subgroups are defined (5-HT,-,) of which three are further divided into two or more subtypes (5-HTIA,B,D,E, 5-HT2, and , , ) [15] . 5-HT may inhibit (5-HTJ or facilitate (5-HT2) the release of acetylcholine from nerves. Similarly, 5-HT may contract or relax smooth muscle directly. For example, 5-HT,, receptors, present on human intestinal muscle cells, mediate contraction of longitudinal muscle [ 161. 5-HT2, and 5-HT4 receptors, also present on human intestinal muscle cells, have opposite effects, the former mediating contraction and the latter mediating relaxation of smoth muscle cells [17] .
The aim of the present study was to investigate the effect of systematically administered 5-HT on the MMC in healthy humans. Furthermore, we intended to study the concentration-effect relationship for 5-HT by measurements of its plasma levels and to analyse the relationship between plasma 5-HT and the urinary excretion of both 5-HT and its main metabolite, 5-hydroxyindole acetic acid (5-HIAA).
MATERIALS A N D METHODS
Twenty-two healthy volunteers, 12 males and 10 females [mean age 28 (range 2 1-39) years], participated in the study. Two subjects participated in two different experiments, with at least 1 month between the experiments. The study protocol was approved by the Ethics Committee of the Karolinska Hospital, and informed consent was obtained from all volunteers.
Experimental protocol
Experiments were undertaken after an overnight fast during a period of 8 h, with subjects in the recumbent position. Each experiment consisted of two consecutive motility registration periods of 4 h each. The controls (n = 8) received saline (0.9Oh NaC1) during both 4-h periods for recordings of basal gastrointestinal motor activity. In the experimental groups, saline was given during the first 4-h period and 5-HT at doses of either 15 nmol min-' * kg-' (n = 8) or 60 nmol-min-'.kg-' (n = 8) during the second 4-h period.
Intestinal motility recordings
The motility pattern of the proximal small intestine was monitored by means of a multichannel polyvinylchloride tube (William Cook, Bjaeverskov, Denmark) . The tube was 250 cm in length and 4.7 mm in outer diameter, and had six channels 0.7 mm in width ending as side-holes at different levels. The tube had a set of four side-holes 3 cm apart for recordings of duodenal motility, and 10 cm further aborally another two side-holes 10 cm apart for recordings of duodenojejunal motility. The tube was passed through a nostril. Fluoroscopy was used to position the tube in the small intestine, with the most distal side-hole 10 cm aboral to the angle of Treitz. Each channel was continuously perfused with degassed water from a low-compliance pneumohydraulic system (Amdorfer Medical Specialities, Greendale, WI, U.S.A.). The channels were connected to external pressure transducers (Synectics, Stockholm, Sweden). Digital recordings were attained by connecting the pressure transducers via a PC POLYGRAPH HR (Synectics) to a personal computer (486D/66 MHz, Dell Corporation, Austin, TX, U.S.A.). The software program used was POLY-GRAM LOWER GI 6.31C3 (Synectics) with a sampling frequency of 4-16 Hz. The pressure rise velocity upon sudden occlusion of the recording system exceeded 200 mmHg/s in each channel.
Analysis of motility recordings
Recordings were inspected by two independent observers who worked separately and agreed upon the presence or absence of motor patterns. Contractions exceeding a cut-off amplitude of 10 mmHg at the angle of Treitz were included in the analysis. MMCs were identified according to the criteria of Vantrappen et al. [9] , i.e.: (a) appearance of uninterrupted bursts of pressure waves with a frequency of 11-12 contractions per min (phase 111), (b) aboral migration of phase I11 activity passing at least the distal two registration points, and (c) a period of complete quiescence after phase 111 activity. Phase I11 of MMC (activity front) was defined as the presence of uninterrupted phasic pressure changes for at least 2 min at the maximum frequency for that locus. The duration of phase I11 at the angle of Treitz was measured from onset of regular contractions to quiescence. The propagation velocity of phase I11 was calculated by dividing the traversed distance from onset of phase I11 by the time interval from one registration point to the next. Phase I1 was defined as having 2 2 phasic contractions per min, whereas phase I was defined as < 2 phasic contractions per min.
The fraction of time occupied by either phase I, I1 or I11 of the MMC cycle was calculated during the control period and during infusion of either saline or 5-HT. The number of contractions and their amplitude, as well as the overall motility index, during the control and infusion periods were calculated.
Urine samples
Urine was collected during the two infusion periods. One portion was acidified with hydrochloric acid (6 mol/l, 0.1-10 ml of urine). A second portion was frozen without additives. The urine was kept frozen (-20 "C) until analysis.
Blood sampling and cell counts
Blood samples were collected after 2 h in the first 4-h period and after 1 and 3 h in the second 4-h period. Clean venipunctures without stasis were performed using 21 G needles connected to 10 ml vacutainer tubes containing 1.0 ml of a platelet stabilizing solution [final concentrations: 9 mmol/l EDTA, 1 mmol/l theophylline and 0.2 pg/ml Iloprost (Schering AG, Berlin, Germany), a stable prostacyclin analogue], as previously described and validated [ 181. All samples were immediately centrifuged at 15 000 g (4 "C, 30 min). Plasma was carefully removed from the mid-layer and stored at -80 "C for measurements of Platelet counts in whole blood anticoagulated with EDTA (final concentration 10 mmol/l) were determined by a semi-automated cell counter (Cellanalyzer 460, Medonic AB, Solna, Sweden).
5-HT.

Determination of 5-HT and 5-HIAA
5-HT in plasma and urine, and 5-HIAA in urine, were analysed by GC-MS as previously described and validated [18, 19] . Urine creatinine was measured by the Jaffk reaction using a Hitachi 717 instrument (Boehringer Mannheim GmbH, Mannheim, Germany).
Chemicals 5-HT (serotonin hydrochloride) was purchased from Fluka Chemie AG (Neu-Ulm, Germany). The compound was dissolved and diluted in sterile 0.9 YO NaCl and the solution was filtered (Millex-Micropore, pore size 0.22 pm) to sterility by the Karolinska Hospital Pharmacy. Ten-millilitre vials were prepared containing sterile stock solution (100 pmol/ml) and ascorbic acid (17.6 pg) was added as antioxidant.
Saline (NaCl, 154 mmol/l) for intravenous infusion was purchased from Kabi-Pharmacia (Uppsala, Sweden).
Vital signs
Measurements of haemodynamic and respiratory parameters started 2 h before commencing 5-HT infusions and continued throughout the experiments. Heart rate, as well as systolic and diastolic blood pressures, was monitored every 15 min, while respiratory frequency and peak expiratory flow were monitored every 30 min.
Statistics
Results are presented as medians and interquartile range, except for haemodynamic data which are presented as mean and 95% confidence interval. Kruskal-Wallis one-way analysis of variance, MannWhitney's U-test or Wilcoxon's signed-rank test were used where appropriate. P < 0.05 was considered significant.
RESULTS
Baseline motility of small intestine
In control studies with saline, the MMC pattern did not differ between the two recording periods. No changes were observed with regard to either the frequency of phase I11 of the MMC or the duration, propagation velocity, contraction frequency or motility index of phase I11 during the two periods (Tables  1 and 2 , Figures 1 and 2) .
The time fraction of MMC occupied by phase I, I1 and I11 did not differ during the two periods (Figure 3 ).
Effects of 5-HT on motility of small intestine
Infusion of 5-HT increased the number of phase I11 of MMC in a dose-dependent manner. However, at the dose of 60 nmol . min-' * kg-' some MMC started in the proximal jejunum instead of in the proximal duodenum ( Figure 1 and Table 1 ).
The interval between phase I11 decreased dosedependently during infusion of 5-HT as the number of MMC increased (Figure 2) .
The time fraction of MMC occupied by phase I did not change during infusion of 5-HT, whereas phase I11 increased dose-dependently, and phase I1 decreased to a corresponding extent during infusion of 5-HT ( Figure 3) .
5-HT dose-dependently increased the propagation velocity of phase I11 as well as the amplitude of contractions belonging to phase 111. However, the contraction frequency, motility index and duration of phase I11 did not change during infusion of 5-HT ( Table 2) .
Effect on vital functions and side effects of 5-HT
Although 5-HT infusion did not influence systolic or diastolic blood pressures at either dose level, an increase in heart rate was observed at the high-dose level from 60.5 (57.5-66.0) beats/min at baseline to a maximum of 72 (72-72) beats/min after 30min of infusion. Respiratory rate and peak expiratory flow were not altered during infusion of 5-HT at either dose. Platelet counts in peripheral venous blood decreased slightly over time during infusion of both 5-HT and saline.
All subjects receiving 5-HT experienced smarting pain in the arm where the infusion was given. In the group receiving 5-HT at a dose of 60 nmol ernin-' * kg-' abdominal cramps were noted in four subjects, nausea in three, mental discomfort in three and vomiting in concentration of 5-HT and the stimulatory effect on phase I11 of MMC was demonstrated, with a correlation coefficient of 0.79 ( Figure 4 ).
Urinary excretion of 5-HT and 5-HIAA
The urinary excretions of 5-HT and 5-HIAA did not change during infusion of saline, but both parameters increased dose-dependently during infusion of 5-HT ( Table 4) .
DISCUSSION
The present study shows that the interdigestive rhythm of the small intestine in man is dose-dependently stimulated by circulating 5-HT, as verified by an increased number of phase I11 of MMC, and an increased propagation velocity and amplitude of contractions during phase 111. The effect was shown to positively correlate to the plasma concentration of 5-HT. The present results confirm and extend our previous findings with bolus injections of and studies in which 5-HT has been shown to stimulate the contractile activity of the small intestine in man [8] .
The phase I11 activity induced by 5-HT in this study meets all the criteria of phase I11 postulated by Vantrappen et al. [9] , namely contraction frequency, aboral migration of phase I11 activity passing at least the distal two registration points, and a period of complete quiescence after phase I11 activity.
The 5-HT-induced phase I11 activity originated in the small intestine. This is in accordance with the effects of sumatriptan, a 5-HT, receptor agonist, which induces premature intestinal phase I11 activity and increases the proportion of phase I11 originating in the jejunum instead of in the stomach [20]. Both 5-HT (present data) and sumatriptan [20] increase the fraction of time occupied by phase I11 at the expense of phase 11. Furthermore, treatment with the selective 5-HT uptake inhibitor, paroxetine, enhances intestinal motility in humans [13] . Thus, the present data are supported by pharmacological data indicating that 5-HT is involved in the initiation and control of MMC in humans.
A role for 5-HT in the regulation of MMC has also been proposed in other species such as pigs, opossums, rats and guinea pigs. 5-HT has been shown to increase both the cycling frequency and propagation velocity of 5-HT2 receptors on smooth muscle cells may increase their contractile force. The plasma concentration of 5-HT, as well as the urinary excretion of 5-HT and 5-HIAA, increased dose-dependently during infusion of 5-HT. The plasma concentration of 5-HT, however, increased by less than expected with the doses given, indicating a very rapid clearance from plasma. Pharmacokinetic parameters for 5-HT were not calculated in the present study, but a comparison with the turnover of other biogenic amines, such as catecholamines, is relevant. Thus infusion of noradrenaline, which has a half-life of approximately 1 min in plasma, elevated arterial plasma noradrenaline levels almost 20-fold, from basal levels of approximately 1 nmol/l, at an infusion rate of 0.5 nmol.min-'.kg-' [5] . In the present study, 5-HT infusion at the rate of 60 nmol.min-'-kg-', i.e. 120 times higher than the dose of noradrenaline used by Hjemdahl and Linde [5] , elevated venous plasma 5-HT only 10-fold, demonstrating a still more rapid turnover of 5-HT in plasma. Early animal studies indicated an extremely short half-life for 5-HT in plasma [6, 30] , and our present data are compatible with these observations.
It can be speculated that 5-HT is rapidly cleared from plasma via uptake by platelets and endothelial cells together with extensive metabolism in the liver and lungs. The rapid clearance of 5-HT from plasma suggests that 5-HT exerts its stimulatory action locally, after release from enteric neurons, enterochromaffin cells or platelets.
In the present study 5-HT, at doses resulting in a 5-to 12-fold increase of the plasma concentration of 5-HT, stimulated the motility of the small intestine and caused abdominal symptoms. In this connection, a comparison can be made to the carcinoid syndrome which is characterized by attacks of, among other things, cutaneous flushing and diarrhoea. The diarrhoea can be explained by either intestinal hypersecretion or intestinal hypermotility, or both. In a study by Ahlman et al. [31] , attacks of carcinoid syndrome were provoked by intravenous pentagastrin. They found an increase in the whole-blood concentration of 5-HT accompanied by cutaneous flushing and abdominal symptoms such as borborrhygmi, urgency and colicky cramps. The abdominal symptoms were prevented or relieved by pretreatment with the 5-HT,-receptor antagonist ketanserin. Against this background, our findings indicate that 5-HT is involved in the pathophysiology of diarrhoea in the carcinoid syndrome in part by stimulating motility of the small intestine.
5-HIAA is normally the predominant metabolite of 5-HT [32] . It has been shown that over 90% of total body 5-HT turnover is reflected by the urinary excretion of 5-HIAA [33] . In the present study, the urinary excretion of 5-HT increased approximately 6-fold while the urinary excretion of 5-HIAA increased 75-fold during infusion of 5-HT at the highest dose level.
The side effects of 5-HT in our study differ somewhat from earlier human studies. In the study by Hendrix et al. [S] , intravenous bolus injections of 5-HT, at doses approximately three times higher than in our study, caused a transitory burning sensation in the throat, tongue, lips and cheeks together with transient tachypnoea and occasionally difficulties in breathing. A possible explanation for the difference in side effects is the doses used and the mode of administration of 5-HT. A higher dose and a rapid injection should result in higher peak concentrations in plasma and a greater risk of side effects. Our finding that 5-HT increases heart rate is in accordance with the demonstration of 5-HT4 receptors in the human right atrium, mediating positive inotropic and chronotropic effects [34] .
In conclusion, this study shows that 5-HT infusion stimulates the fasting motility with more frequent and rapidly propagating phase I11 of MMC. It is therefore suggested that 5-HT released locally, from neurons or enterochromaffin cells, may participate in the control of small intestinal interdigestive motility.
